.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR06_EmtricitabineTenofovirDisoproxil.EmtricitabineTenofovirDisoproxil .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR06_EmtricitabineTenofovirDisoproxil.EmtricitabineTenofovirDisoproxil| name: | EmtricitabineTenofovirDisoproxilAndEfavirenz |
| ATC code: | J05AR06 |
| route: | oral |
| n-compartments | 1 |
A fixed-dose combination of three antiretroviral medications: emtricitabine (a nucleoside reverse transcriptase inhibitor), tenofovir disoproxil fumarate (a nucleotide reverse transcriptase inhibitor), and efavirenz (a non-nucleoside reverse transcriptase inhibitor). Used for the treatment of HIV-1 infection in adults and children and is currently approved for use.
Pharmacokinetics in healthy HIV-negative adults receiving a single oral fixed-dose combination tablet (emtricitabine 200 mg, tenofovir disoproxil fumarate 300 mg, efavirenz 600 mg) under fasting conditions.